On April 3, 2026, Affinia Therapeutics announced that Health Canada approved the company to begin its UPBEAT clinical trial, a Phase 1/2 study testing the first gene therapy designed to treat BAG3-associated dilated cardiomyopathy (BAG3 DCM). The U.S. FDA had already cleared the same trial in February 2026, and the agency granted Fast Track designation in March. This is the first time a gene therapy targeting a genetic form of heart failure has reached human trials in multiple countries simultaneously.
Affinia Therapeutics estimates that approximately 70,000 people are living with BAG3 DCM across the U.S., Canada, Europe, and the U.K. this is a significant moment for the field. There are currently no treatments that address the genetic cause of the disease. Every existing option manages symptoms. These two trial approvals mark the beginning of a different approach: replacing the broken gene itself.
15 Years from Gene Discovery to First Patient
The path from discovering BAG3's role in heart disease to beginning a clinical trial took about 15 years of research across multiple institutions and continents.
The story begins in 2006, when Patrick Ellinor and colleagues published a genome-wide association study that identified a new genetic region on chromosome 10 linked to dilated cardiomyopathy and sudden cardiac death (Ellinor et al., 2006). At the time, researchers did not yet know which specific gene in the region was responsible.
That answer came in 2011. Norton et al. used copy number variation analysis and exome sequencing to identify a deletion mutation in the BAG3 gene that appeared consistently in family members with heritable dilated cardiomyopathy (Norton et al., 2011). The same year, Villard and colleagues published a separate genome-wide association study linking BAG3 variants to heart failure from DCM (Villard et al., 2011). These two studies, published independently, confirmed that BAG3 was a major genetic cause of the disease.
Over the next decade, research teams in the U.S., Europe, and Japan worked to understand exactly how BAG3 mutations damage the heart. The picture that emerged: BAG3 protein acts like a quality control system inside heart muscle cells. It helps clear out damaged and misfolded proteins, maintaining the structural integrity of the sarcomere (the contractile unit of heart muscle). When the gene is mutated and the protein is deficient, damaged proteins accumulate, and the heart muscle gradually weakens.
A 2021 study published in Nature Communications demonstrated that restoring BAG3 levels using adeno-associated virus (AAV) gene therapy in mice with heart failure improved both sarcomere protein turnover and cardiac function (Martin et al., 2021). This was a critical proof-of-concept that replacing the missing gene could reverse the damage, not just slow it down.
How Common Is BAG3 DCM?
Dilated cardiomyopathy overall affects about 1 in 250 people worldwide, making it one of the more common forms of heart disease. Within that population, BAG3 mutations account for roughly 2 to 4% of cases, making it the second most common genetic cause of DCM after titin mutations (Dominguez et al., 2018).
The clinical profile of BAG3 DCM is distinct from other genetic cardiomyopathies. Disease penetrance reaches about 80% in people over age 40 who carry the mutation. Men tend to be diagnosed earlier (average age 35) than women (average age 41). Unlike some other genetic forms like LMNA-related DCM, serious ventricular arrhythmias are relatively uncommon at about 1% per year. The primary clinical problem is progressive heart failure, with transplant, LVAD, or heart failure death occurring at 4.3% annually (Dominguez et al., 2018).
Two Companies, Two Approaches
Affinia Therapeutics is not the only company developing a gene therapy for BAG3 DCM. Rocket Pharmaceuticals received FDA clearance for its own program, RP-A701, in June 2025 and expects to dose its first patient by mid-2026. The two therapies take different technical approaches to the same problem, which is good news for patients.
Affinia Therapeutics: AFTX-201 (UPBEAT Trial)
Affinia was founded in 2019 (originally as TDTx Inc.) based on capsid engineering research from Luk Vandenberghe's laboratory at Harvard. The company has raised $241 million in total funding, including a $40 million Series C round in October 2025 led by New Enterprise Associates with strategic investment from Eli Lilly (Affinia Therapeutics, 2025).
AFTX-201 uses a proprietary engineered AAV capsid designed specifically for heart muscle delivery. According to Affinia, the capsid achieves cardiac transduction at doses 5 to 10 times lower than conventional AAV serotypes like AAV9 or AAVrh74. Lower doses matter because high-dose AAV gene therapies have been associated with serious immune responses and liver toxicity in other disease programs.
The UPBEAT trial is a multicenter, open-label Phase 1/2 study enrolling adults aged 18 to 55 with genetically confirmed truncating BAG3 mutations, left ventricular ejection fraction below 45%, and New York Heart Association Class II or III heart failure. Participants receive a single intravenous infusion of AFTX-201. The primary endpoint is safety and tolerability through 52 weeks, with secondary endpoints looking at cardiac function and BAG3 protein levels.
Rocket Pharmaceuticals: RP-A701
Rocket Pharmaceuticals is taking a more conventional AAV approach, using an AAVrh.74 vector to deliver the BAG3 gene. The company received FDA IND clearance in June 2025 and has described RP-A701 as a first-in-class treatment for BAG3 DCM (Rocket Pharmaceuticals, 2025). Their Phase 1 trial will start with adults who have implantable cardioverter defibrillators and advanced disease, focusing on safety in the highest-risk patients first.
Having two independent programs in development increases the odds that at least one reaches patients. It also creates healthy competition that tends to accelerate timelines. The two approaches differ in capsid technology, dosing strategy, and initial patient population, which means even if one encounters setbacks, the other may still succeed.
What the Regulatory Milestones Mean
The regulatory trajectory for AFTX-201 has been fast by rare disease standards. Here is the timeline:
February 2026: FDA accepts IND application for the UPBEAT trial. March 2026: FDA grants Fast Track designation, which provides more frequent regulatory meetings and the potential for priority review if the therapy reaches the approval stage. April 2026: Health Canada approves the UPBEAT trial to begin enrolling patients in Canada. Affinia also holds EMA Orphan Drug Designation in Europe.
Fast Track designation is meaningful because it signals that the FDA recognizes both the severity of the disease and the lack of existing treatments. It does not guarantee approval, but it does mean the agency is committed to working closely with the company throughout the development process.
What This Means for Patients and Families
If you or a family member has been diagnosed with BAG3-associated dilated cardiomyopathy, the UPBEAT trial is now actively enrolling. Eligibility requires a genetically confirmed truncating BAG3 mutation, so if you have not had genetic testing, that would be the first step. Many cardiology centers can order a cardiomyopathy gene panel, and some patient advocacy organizations offer guidance on access.
A few important things to keep in mind: this is a Phase 1/2 trial, which means the primary goal is to establish that the therapy is safe. Efficacy data will come, but it will take time. The trial's primary completion date is projected for December 2028. Gene therapy is also a one-time treatment by design, which means the decision to enroll carries long-term considerations that are worth discussing with your care team.
For the broader dilated cardiomyopathy community, this trial is a proof of concept for something larger. If gene therapy works for BAG3 DCM, the same approach could potentially be adapted for other genetic forms of heart failure caused by mutations in titin, lamin A/C, and other genes. That is not a guarantee, but the scientific groundwork is being laid right now.